scholarly journals Fetal and placental vascular tumors: persistent fetal hyperdynamic status predisposes to poorer long-term neurodevelopmental outcome

2014 ◽  
Vol 43 (6) ◽  
pp. 658-661 ◽  
Author(s):  
C. Iacovella ◽  
N. Chandrasekaran ◽  
A. Khalil ◽  
A. Bhide ◽  
A. Papageorghiou ◽  
...  
Keyword(s):  
Neurodevelopmental Outcome ◽  
Vascular Tumors

scholarly journals Oral melatonin as a new tool for neuroprotection in preterm newborns: study protocol for a randomized controlled trial

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Francesca Garofoli ◽  
Stefania Longo ◽  
Camilla Pisoni ◽  
Patrizia Accorsi ◽  
Micol Angelini ◽  
...  
Keyword(s):  
Preterm Birth ◽  
Preterm Infants ◽  
Neurodevelopmental Outcome ◽  
Lipid Peroxidation Product ◽  
Cerebral Magnetic Resonance Imaging ◽  
Neurodevelopmental Impairment ◽  
Anti Oxidant ◽  
Preterm Newborns

Abstract Background Prevention of neurodevelopmental impairment due to preterm birth is a major health challenge. Despite advanced obstetric and neonatal care, to date there are few neuroprotective molecules available. Melatonin has been shown to have anti-oxidant/anti-inflammatory effects and to reduce brain damage, mainly after hypoxic ischemic encephalopathy. The planned study will be the first aiming to evaluate the capacity of melatonin to mitigate brain impairment due to premature birth. Method In our planned prospective, multicenter, double-blind, randomized vs placebo study, we will recruit, within 96 h of birth, 60 preterm newborns with a gestational age ≤ 29 weeks + 6 days; these infants will be randomly allocated to oral melatonin, 3 mg/kg/day, or placebo for 15 days. After the administration period, we will measure plasma levels of malondialdehyde, a lipid peroxidation product considered an early biological marker of melatonin treatment efficacy (primary outcome). At term-equivalent age, we will evaluate neurological status (through cerebral ultrasound, cerebral magnetic resonance imaging, vision and hearing evaluations, clinical neurological assessment, and screening for retinopathy of prematurity) as well as the incidence of bronchodysplasia and sepsis. We will also monitor neurodevelopmental outcome during the first 24 months of corrected age (using the modified Fagan Test of Infant Intelligence at 4–6 months and standardized neurological and developmental assessments at 24 months). Discussion Preterm birth survivors often present long-term neurodevelopmental sequelae, such as motor, learning, social-behavioral, and communication problems. We aim to assess the role of melatonin as a neuroprotectant during the first weeks of extrauterine life, when preterm infants are unable to produce it spontaneously. This approach is based on the supposition that its anti-oxidant mechanism could be useful in preventing neurodevelopmental impairment. Considering the short- and long-term morbidities related to preterm birth, and the financial and social costs of the care of preterm infants, both at birth and over time, we suggest that melatonin administration could lead to considerable saving of resources. This would be the first study addressing the role of melatonin in very low birth weight preterm newborns, and it could provide a basis for further studies on melatonin as a neuroprotection strategy in this vulnerable population. Trial registration ClinicalTrials.gov NCT04235673. Prospectively registered on 22 January 2020.

scholarly journals Long-Term Neurodevelopmental Outcome of Monochorionic and Matched Dichorionic Twins

PLoS ONE ◽  
2009 ◽  
Vol 4 (8) ◽  
pp. e6815 ◽  
Author(s):  
Karien E. A. Hack ◽  
Corine Koopman-Esseboom ◽  
Jan B. Derks ◽  
Sjoerd G. Elias ◽  
Martin J. K. de Kleine ◽  
...  
Keyword(s):  
Neurodevelopmental Outcome

390: Long-term neurodevelopmental outcome in twin-to-twin transfusion syndrome (TTTS) in the eurofoetus trial

2008 ◽  
Vol 199 (6) ◽  
pp. S118 ◽  
Author(s):  
Lisa Örtqvist ◽  
Bussieres Laurence ◽  
Staraci Stephanie ◽  
Fermanian Christophe ◽  
Ville Yves
Keyword(s):  
Neurodevelopmental Outcome

scholarly journals Neurodevelopmental outcome of babies with hypoxic ischemic encephalopathy

2017 ◽  
Vol 5 (7) ◽  
pp. 3197
Author(s):  
Sirajuddin Nazeer ◽  
Senthilkumar K. ◽  
Thangavel A. ◽  
Uma Maheswari M.
Keyword(s):  
Neurological Outcome ◽  
Neurodevelopmental Outcome ◽  
Hypoxic Ischemic Encephalopathy ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Mri Brain ◽  
Early Markers ◽  
Cdc Grading ◽  
Ischemic Encephalopathy

Background: The aim of the study was to find out the neurodevelopmental outcome of babies with hypoxic ischemic encephalopathy at 6 months of age and to predict early markers of abnormal neurological outcome in those babies.Methods: 50 babies admitted with hypoxic ischemic encephalopathy were enrolled in this prospective study and followed up at 3 and 6 months of age at Mahatma Gandhi Memorial Government Hospital, Trichy. The neurological outcome of the babies was assessed by CDC grading of motor milestones, Trivandrum development screening chart, Amiel Tison angles head circumference and weight measured. USG cranium was done for all the babies and MRI brain was done in babies with abnormal neuro sonogram and abnormal outcome. Vision and hearing were tested clinically.Results: The incidence of abnormal neurological outcome was 14%. The early markers predicting abnormal neurological sequele are identified.Conclusions: Early identification of abnormal neuro behaviour helps in starting early intervention to improve the long term outcome.

scholarly journals Long-term neurodevelopment in children born with esophageal atresia: a systematic review

2021 ◽  
Author(s):  
Camille E van Hoorn ◽  
Chantal A ten Kate ◽  
Andre B Rietman ◽  
Leontien C C Toussaint-Duyster ◽  
Robert Jan Stolker ◽  
...  
Keyword(s):  
Cognitive Development ◽  
Motor Function ◽  
Esophageal Atresia ◽  
Current Knowledge ◽  
Neurodevelopmental Outcome ◽  
Cognitive Outcome ◽  
Term Outcome ◽  
Long Term Outcome ◽  
The One

Summary Background Although the survival rate of esophageal atresia (EA) has increased to over 90%, the risk of functional long-term neurodevelopmental deficits is uncertain. Studies on long-term outcomes of children with EA show conflicting results. Therefore, we provide an overview of the current knowledge on the long-term neurodevelopmental outcome of children with EA. Methods We performed a structured literature search in Embase, Medline Ovid, Web of Science, Cochrane CENTRAL, and Google scholar on November 8, 2020 with the keywords ‘esophageal atresia’, ‘long-term outcome’, ‘motor development’, ‘cognitive development’, and ‘neurodevelopment’. Results The initial search identified 945 studies, of which 15 were included. Five of these published outcomes of multiple tests or tested at multiple ages. Regarding infants, one of six studies found impaired neurodevelopment at 1 year of age. Regarding preschoolers, two of five studies found impaired neurodevelopment; the one study assessing cognitive development found normal cognitive outcome. Both studies on motor function reported impairment. Regarding school-agers, the one study on neurodevelopmental outcome reported impairment. Cognitive impairment was found in two out of four studies, and motor function was impaired in both studies studying motor function. Conclusions Long-term neurodevelopment of children born with EA has been assessed with various instruments, with contrasting results. Impairments were mostly found in motor function, but also in cognitive performance. Generally, the long-term outcome of these children is reason for concern. Structured, multidisciplinary long-term follow-up programs for children born with EA would allow to timely detect neurodevelopmental impairments and to intervene, if necessary.

scholarly journals Long-term neurodevelopmental outcome after intrauterine transfusion for hemolytic disease of the fetus/newborn: the LOTUS study

2012 ◽  
Vol 206 (2) ◽  
pp. 141.e1-141.e8 ◽  
Author(s):  
Irene T. Lindenburg ◽  
Vivianne E. Smits-Wintjens ◽  
Jeanine M. van Klink ◽  
Esther Verduin ◽  
Inge L. van Kamp ◽  
...  
Keyword(s):  
Neurodevelopmental Outcome ◽  
Hemolytic Disease ◽  
Intrauterine Transfusion

Prediction of long-term neurodevelopmental outcome in preterm infants using trajectories of general movement assessments

2018 ◽  
Vol 38 (10) ◽  
pp. 1398-1406 ◽  
Author(s):  
Jessie van Dyk ◽  
Paige Church ◽  
Sharon Dell ◽  
Teresa To ◽  
Maureen Luther ◽  
...  
Keyword(s):  
Preterm Infants ◽  
Neurodevelopmental Outcome ◽  
General Movement

Jaundice in Healthy, Term Neonates: Do We Need New Action Levels or New Approaches?

PEDIATRICS ◽  
1992 ◽  
Vol 89 (5) ◽  
pp. 827-829
Author(s):  
AUDREY K. BROWN ◽  
DANIEL S. SEIDMAN ◽  
DAVID K. STEVENSON
Keyword(s):  
Neurodevelopmental Outcome ◽  
Alexander Pope ◽  
Neurologic Injury ◽  
Term Infants ◽  
Ample Evidence ◽  
Term Neonates ◽  
Neurodevelopmental Impairment ◽  
New Guidelines ◽  
Action Levels

All seems infected that th' infected spy, As all looks yellow to the jaundiced eye. —Alexander Pope An Essay on Criticism, 1711 We take note of Alexander Pope's admonition, and we are reminded by others that, from their perspective, the evidence is unconvincing that moderate neonatal hyperbilirubinemia adversely affects the neurodevelopmental outcome of healthy, term infants. Moreover, although there is ample evidence that high levels of bilirubin may be associated with neurologic injury, a linear relationship between neonatal serum bilirubin levels and long-term neurodevelopmental impairment does not seem to exist.1 Such observations have been recognized for some time2,3 and have encouraged some of our colleagues to propose new guidelines for the treatment of jaundice in well, term infants.4,5

Sign in / Sign up

Export Citation Format

Share Document